MECOM and leukemia: Moreover, driver genes, as RAS, FLT3, NPM1, EVI1 and KMT2A shape the interaction between polyamine metabolic pathway and leukemia-supporting functions, resulting in selective vulnerabilities, as unveiled by drugs targeting PRMT5.